Radiothérapie externe accélérée postopératoire des carcinomes épidermoïdes localement évolués de la sphère ORL: Étude prospective de phase II

Keyphrases

• Acceleration Radiation 33%
• Acute Morbidity 33%
• Acute Radiation 33%
• Concomitant Boost 33%
• Disease-free Survival 33%
• Distant Metastasis 33%
• Dysphagia 33%
• External Beam Radiotherapy 33%
• Extracapsular 33%
• Head-and-neck 100%
• Hypopharynx 33%
• Infiltration 33%
• Intraoperative Radiation Therapy 100%
• Local Control Rate 33%
• Local Relapse 33%
• Locoregional Control Rate 33%
• Locoregional Recurrence 33%
• Male-to-female Ratio 33%
• Maxillary Sinus 33%
• Median Time 33%
• Mucositis 33%
• Oral Cavity 33%
• Oropharynx 33%
• Overall Treatment Time 33%
• Positive Surgical Margin 33%
• Primary Unknown 33%
• Published Data 33%
• Radiation Therapy 66%
• Salivary Gland 33%
• Skin Erythema 33%
• Squamous Cell Carcinoma of Head 100%
• Therapy-related 33%
• Time to Relapse 33%
• Weight Loss 33%

Medicine and Dentistry

• Cancer of Unknown Primary Origin 20%
• Disease Free Survival 20%
• Distant Metastasis 20%
• Erythema 20%
• External Beam Radiotherapy 20%
• Hypopharynx 20%
• Larynx 20%
• Maxillary Sinus 20%
• Mucositis 20%
• Neck 100%
• Oral Cavity 20%
• Oropharynx 20%
• Plummer-Vinson Syndrome 20%
• Prospective Study 100%
• Radiation Therapy 100%
• Recurrent Disease 20%
• Salivary Gland 20%
• Squamous Cell Carcinoma 100%
• Surgical Margin 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Cancer of Unknown Primary Site 33%
• Disease Free Survival 33%
• Distant Metastasis 33%
• Dysphagia 33%
• Erythema 33%
• Mucosa Inflammation 33%
• Prospective Study 100%
• Recurrent Disease 33%
• Squamous Cell Carcinoma 100%